参考文献
1.WHO.Global tuberculosis report 2018［EB/OL］.Geneva: WHO, 2018.
2.John E, Bennett Raphael Dolin, Martin J, et al.Principles and practice of infectious diseases［M］.Amsterdam: Elsevier, 2014.
3.杨宝峰，陈建国.药理学［M］.9版.北京：人民卫生出版社，2018.
4.Lindsay Grayson M, Cosgrove S E, Suzanne Crowe, et al.Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs［M］.UK: CRC Press of Taylor & Francis Group, 2017.
5.Garg RK, Jain A, Malhotra HS, Agrawal A, Garg R.Drug-resistant tuberculous meningitis［J］.Expert review of anti-infective therapy.2013; 11(6): 605—621.
6.WHO.Treatment of tuberculosis: guidelines［EB/OL］.4th ed.Geneva: WHO, 2010.
7.Belanger AE, Besra GS, Ford ME, et al.The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol［J］.Proceedings of the National Academy of Sciences of the United States of America.1996; 93(21): 11919—11924.
8.Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D.Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis［J］.American journal of respiratory and critical care medicine.2003; 167(11): 1472—1477.
9.Salfinger M, Heifets LB.Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method［J］.Antimicrobial agents and chemotherapy.1988; 32(7): 1002—1004.
10.Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR.Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin［J］.The New England journal of medicine.1993; 328(8): 527—532.
11.Donald PR, Maritz JS, Diacon AH.Pyrazinamide pharmacokinetics and efficacy in adults and children［J］.Tuberculosis.2012; 92(1): 1—8.
12.Budha NR, Lee RE, Meibohm B.Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs［J］.Current medicinal chemistry.2008; 15(8):809—825.
13.中华医学会结核病学分会耐多药结核病短程治疗中国专家共识编写组.耐多药结核病短程治疗中国专家共识［J］.中华结核和呼吸杂志.2019，42（1）：5—8.
14.Burman WJ, Gallicano K, Peloquin C.Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials［J］.Clinical pharmacokinetics.2001; 40(5): 327—341.
15.Tam CM, Chan SL, Lam CW, et al.Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis.Initial report［J］.American journal of respiratory and critical care medicine.1998; 157(6 Pt 1): 1726—1733.
16.Modongo C, Pasipanodya JG, Zetola NM, et al.Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients［J］.Antimicrobial agents and chemotherapy.2015; 59(10): 6337—6343.
17.Jenkins A, Thomson AH, Brown NM, et al.Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review［J］.The Journal of antimicrobial chemotherapy.2016; 71(10): 2754—2759.
18.Dirain CO, Ng Mrav, Milne-Davies B, et al.Evaluation of Mitoquinone for Protecting Against Amikacin-Induced Ototoxicity in Guinea Pigs［EB/OL］.Otology & neurotology :official publication of the American Otological Society, American Neurotology Society ［and］European Academy of Otology and Neurotology.2018; 39(1): 111—118.(https://www.daowen.com)
19.van Heeswijk RP, Dannemann B, Hoetelmans RM.Bedaquiline: a review of human pharmacokinetics and drug-drug interactions［J］.The Journal of antimicrobial chemotherapy.2014; 69(9): 2310—2318.
20.Singh S, Nautiyal A.Aortic Dissection and Aortic Aneurysms Associated with Fluoroquinolones: A Systematic Review and Meta-Analysis［J］.The American journal of medicine.2017; 130(12): 1449—1457.
21.Lee CC, Lee MT, Chen YS, et al.Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone［J］.JAMA internal medicine.2015; 175(11): 1839—1847.
22.Inghammar M, Svanstrom H, Melbye M, Pasternak B, Hviid A.Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study［J］.Bmj.2016; 352(2): i843.
23.Pasternak B, Inghammar M, Svanstrom H.Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study［J］.Bmj.2018; 360(3): k678.
24.Bidell MR, Lodise TP.Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?［J］.Pharmacotherapy.2016; 36(6): 679—693.
25.Tillotson GS.FDA and the safe and appropriate antibiotic use of fluoroquinolones［J］.The Lancet Infectious diseases.2016; 16(3): e11—e12.
26.Tulkens PM, Arvis P, Kruesmann F.Moxifloxacin safety: an analysis of 14 years of clinical data［J］.Drugs in R&D.2012; 12(2): 71—100.
27.中华医学会结核病学分会.利奈唑胺抗结核治疗专家共识［J］.中华结核和呼吸杂志.2018，41（1）：14—19.
28.中华医学会结核病学分会.抗结核新药贝达喹啉临床应用专家共识［J］.中华结核和呼吸杂志.2018，41（6）：461—466.
29.Sood G, Parrish N.Outbreaks of nontuberculous mycobacteria［J］.Current opinion in infectious diseases.2017; 30(4): 404—409.
30.Griffith DE, Aksamit T, Brown-Elliott BA, et al.An official ATS/IDSA statement: diagnosis,treatment, and prevention of nontuberculous mycobacterial diseases［J］.American journal of respiratory and critical care medicine.2007; 175(4): 367—416.
31.Haworth CS, Banks J, Capstick T, et al.British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)［J］.Thorax.2017; 72(Suppl 2): ii1—ii64.
32.中华医学会结核病学分会.非结核分枝杆菌病诊断与治疗专家共识［J］.中华结核和呼吸杂志.2012，35（8）：572—580.
33.中华医学会结核病学分会.非结核分枝杆菌病诊断与处理指南［J］.中华结核和呼吸杂志.2000，11（23）：650—653.
34.汪复，张婴元.实用抗感染治疗学［M］.2版.北京：人民卫生出版社，2012.
35.中国防痨协会.耐药结核病化学治疗指南［J］.中国防痨杂志，2015，37（5）：421—469.
36.Mingote LR, Namutamba D, Apina F, et al.The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis affected communities［J］.Lancet.2015; 385(9966): 477—479.